Business Wire

Mellanox Technologies, Ltd Partnering with Hewlett Packard Enterprise to Boost NFV and Telco Network Performance


Mellanox® Technologies, Ltd. (NASDAQ: MLNX), a leading supplier of high-performance, end-to-end interconnect solutions for data center servers and storage systems, today announced an extended partnership with Hewlett Packard Enterprise (HPE). Mellanox is working simultaneously at its own NFV benchmarking facility as well as with HPE and their NFV Infrastructure lab to optimize the Mellanox ConnectX®-4 Lx series of Ethernet adapters on HPE servers. In the Mellanox NFV benchmarking facility the ConnectX®-4 Lx Ethernet adapter with Mellanox DPDK Poll Mode Driver (PMD) has demonstrated near line rate packet processing performance of 33 million packets per second per 25Gb/s port, with zero packet loss, running in HPE’s ProLiant series of server platforms.

The quest for higher I/O bandwidth and network performance continues to mount as businesses and organizations accelerate their digital transformation and rapidly deploy new virtual services and solutions. This is especially true for Communication Service Providers (CSPs) who are moving NFV from concept to deployment. CSP’s must make sure their underlying network infrastructure has enough data packet processing throughput to maintain the Quality of Service their Subscribers expect today. These factors have made 25G Ethernet with high packet handling performance and low processing overhead an attractive option.

Mellanox along with other promoters and hyperscale data center leaders came together to form the 25G Ethernet Consortium ( to define the specification for interoperable 25/50G products. More than 40 consortium member companies have developed products based on the de facto industry standard, and today 25G is poised to experience the most rapid adoption of any previous Ethernet networking speed. Mellanox is the first to market with a 25/50/100Gb/s end-to-end Ethernet family of products including: Spectrum switches, ConnectX-4/4Lx adapters, and LinkX cables. ConnectX-4 Lx 25G Ethernet NICs have been proven to deliver near line rate packet processing performance of 33 million packets per second at zero packet loss, making it an ideal choice for NFV and cloud deployment.

In addition, Mellanox is an active contributor to the Open Compute Project (OCP), bringing 10/25G and 40/50/100G end-to-end interconnect Ethernet designs to the OCP community. These advanced adapter, switch, and interconnect Ethernet products are ideal for CSPs to free their networks to unlock performance, unleash innovation, and enable open platforms that deliver the highest performance, reliability and efficiency and avoid vendor lock in.

“Mellanox is a company that is built on relentless pursuit of network performance and infrastructure efficiency through innovation in silicon design, software development, and active engagement in standard bodies and industry associations. Our end-to-end 25Gb/s Ethernet interconnect portfolio, and a full suite of virtual switching acceleration and offloading capabilities, eliminate the performance bottlenecks normally associated with deploying NFV solutions,” said Kevin Deierling, vice president of marketing at Mellanox Technologies. “Moreover, these groundbreaking performance numbers are achieved through full virtual switch offload on the adapter, resulting in minimal impact on valuable CPU and memory resources, empowering NFV platforms to do what they are supposed to do – perform service and application processing, rather than handling packet I/O.”

“As CSPs deploy NFV in production, they need to ensure their NFV Infrastructure (NFVI) is reliable and can continue to deliver the quality of service their subscribers demand. One aspect of this is making sure their NFVI has the data packet processing performance required to support the service traffic.” said Claus Pedersen, Director of NFV and Telecommunication Segment, HPE Servers. “The HPE Telco NFV Infrastructure lab has worked closely with Mellanox to ensure that Mellanox ConnectX-4 Lx 25Gb/s running on HPE ProLiant servers will enable our CSP customers to achieve the scale, reliability and efficiency they require of their NFV deployments.”

Supporting Resources:

About Mellanox

Mellanox Technologies is a leading supplier of end-to-end InfiniBand and Ethernet interconnect solutions and services for servers and storage. Mellanox interconnect solutions increase data center efficiency by providing the highest throughput and lowest latency, delivering data faster to applications and unlocking system performance capability. Mellanox offers a choice of fast interconnect products: adapters, switches, software, cables and silicon that accelerate application runtime and maximize business results for a wide range of markets including high-performance computing, enterprise data centers, Web 2.0, cloud, storage and financial services. More information is available at

Mellanox, ConnectX, SwitchX, and Virtual Protocol Interconnect are registered trademarks of Mellanox Technologies, Ltd. All other trademarks are property of their respective owners.

Contact information

Mellanox Technologies, Ltd.
Press/Media Contact
McGrath/Power Public Relations and Communications
Allyson Scott, +1-408-727-0351
Investor Contact
Mellanox Technologies
Jeffrey Schreiner, +1-408-916-0012
Israel PR Contact
Gelbart Kahana Investor Relations
Sharon Levin, +972-3-6070567

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on